logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • CD38-directed Cytolytic Antibody class drugs

    FiltersReset Filters
    3 results

    • darzalex

      (Daratumumab)
      Janssen Biotech, Inc.
      Usage: DARZALEX is indicated for adult patients with multiple myeloma, used in various combinations with other therapies for newly diagnosed patients ineligible for stem cell transplant, relapsed or refractory cases after prior treatments, and as monotherapy for patients with extensive treatment history or double-refractory status.

    • darzalex faspro

      (daratumumab and hyaluronidase-fihj (human recombinant))
      Janssen Biotech, Inc.
      Usage: DARZALEX FASPRO is indicated for adult patients with multiple myeloma, either in combination with other therapies (e.g., bortezomib, lenalidomide, dexamethasone) or as monotherapy after multiple prior treatments. It is also indicated for newly diagnosed light chain amyloidosis in combination with bortezomib and dexamethasone, under specific conditions.

    • sarclisa

      (isatuximab)
      Sanofi-Aventis U.S. LLC
      Usage: SARCLISA is indicated for the treatment of adult patients with multiple myeloma in combination with pomalidomide and dexamethasone after at least 2 prior therapies, or with carfilzomib and dexamethasone after 1 to 3 prior lines of therapy.